Julie A. Johnson

Julie A. Johnson's research focuses on pharmacogenetics, the study of how genetic variation affects individual responses to drugs, with particular attention to cardiovascular medications like warfarin and tacrolimus, and to genetic differences across ancestry groups including African Americans. Her work spans genome-wide association studies, drug metabolism enzymes such as CYP2C19, CYP2D6, and CYP3A4/5, and the use of large clinical and genomic datasets to guide personalized drug dosing. She also contributes to broader discussions on clinical translational pharmacology, real-world data, and health disparities in treatment access and outcomes.

Publication output was relatively steady at 19-28 papers per year from 2017-2022, then declined sharply from 2023 onward to roughly 7-13 papers per year, suggesting a slowing pace in recent years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026